Merck recently gained approval for a vaccine called Zostavax for preventing herpes zoster reactivation in elderly people. This live virus vaccine is unusual in that it is to prevent reemergence, not to prevent initial infection. Can the same concept be used for recurrent herpes simplex infection which is much more disabling than herpes zoster in younger people?
Doctor turned coder, Information Systems PhD, OpenMRS & OSCAR EMR wizard, loves Canadian wine and beer, believes in coding to save lives. [Resume]
Latest posts by Bell Eapen (see all)
- Kedro for multimodal machine learning in healthcare - January 25, 2023
- Using OpenFaaS containers in Kubeflow - December 14, 2022
- Six things data scientists in healthcare should know - November 3, 2021